ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

MNKD MannKind Corporation

6.15
0.12 (1.99%)
28 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
MannKind Corporation NASDAQ:MNKD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.12 1.99% 6.15 6.03 6.14 6.15 5.97 5.97 1,432,427 00:49:04

MannKind to Present at 2024 UBS Healthcare Conference

05/11/2024 9:15pm

GlobeNewswire Inc.


MannKind (NASDAQ:MNKD)
Historical Stock Chart


From Oct 2024 to Jan 2025

Click Here for more MannKind Charts.

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference in Rancho Palos Verdes, Calif.

The fireside chat will take place on Tuesday, November 12, at 10:15 a.m. Pacific Time. A link to the live audio webcast of the session will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. A recorded version will also be available on the website for approximately 30 days following the conference.

About MannKindMannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.

This press release was published by a CLEAR® Verified individual.

For MannKind:
Investor Relations
Ana Kapor
(818) 661-5000
Email: ir@mnkd.com

Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com

1 Year MannKind Chart

1 Year MannKind Chart

1 Month MannKind Chart

1 Month MannKind Chart

Your Recent History

Delayed Upgrade Clock